Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Craig Shadur

Nephrology Des Moines, IA Medical Doctor

NPI 1851354674 CMS profile 128935

1215 Pleasant Street, Suite 100, Des Moines, IA 50309

Open in the dashboard

General payments

$314,156

407 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$44,930 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Craig Shadur of Des Moines, IA is reported in the CMS Open Payments database as having received $314,156 across 407 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $44,930 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,740 1
2024 General $13,610 12
2023 General $36,841 31
2022 General $91,078 96
2021 General $81,234 95
2020 General $28,550 46
2019 General $61,103 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Craig Shadur
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Craig Shadur were reported at $1,740. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Craig Shadur Nephrology median Middle half National median
2019 $61,103 $236 $90–$588 $163
2020 $28,550 $135 $46–$364 $114
2021 $81,234 $202 $67–$551 $132
2022 $91,078 $242 $77–$695 $149
2023 $36,841 $254 $84–$766 $160
2024 $13,610 $300 $99–$852 $164
2025 $1,740 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alexion Pharmaceuticals, Inc. $125,239 147 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $107,166 91 payments
  3. AstraZeneca Pharmaceuticals LP $38,918 77 payments
  4. Horizon Therapeutics plc $30,087 50 payments
  5. Amgen Inc. $9,007 18 payments
  6. Otsuka America Pharmaceutical, Inc. $2,265 3 payments
  7. Sanofi-Aventis U.S. LLC $351 1 payment
  8. Calliditas Therapeutics US Inc. $251 2 payments
  9. Mallinckrodt Enterprises LLC $227 5 payments
  10. C. R. Bard, Inc. & Subsidiaries $213 1 payment
  11. Other $431 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $245,422 116 payments
  2. Travel and Lodging $31,494 119 payments
  3. Honoraria $27,425 28 payments
  4. Food and Beverage $6,861 134 payments
  5. Consulting Fee $2,835 6 payments
  6. Education $120 4 payments
Products named General payments · program years 2019–2025
  1. Kerendia $107,166 91 payments
  2. LOKELMA $36,193 64 payments
  3. KRYSTEXXA $30,087 50 payments
  4. ULTOMIRIS Rare Disease $22,492 16 payments
  5. Ultomiris Immunology $19,272 23 payments
  6. Soliris $7,358 17 payments
  7. Parsabiv $6,402 12 payments
  8. FARXIGA $2,526 9 payments
  9. SAMSCA $2,250 1 payment
  10. TAVNEOS $1,900 2 payments
  11. Other $2,078 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

407 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record